본문으로 건너뛰기
← 뒤로

Postbiotic-mediated gut microbiome modulation enhances R-CHOP efficacy in high-risk diffuse large B-cell lymphoma: a case report.

증례보고 1/5 보강
Discover oncology 📖 저널 OA 95.2% 2022: 2/2 OA 2023: 3/3 OA 2024: 36/36 OA 2025: 546/546 OA 2026: 298/344 OA 2022~2026 2025 Vol.17(1) p. 169
Retraction 확인
출처

Liu X, Cheng D, Wang F

📝 환자 설명용 한 줄

This case report describes an adult with high-risk DLBCL (IPI score 4) treated with R-CHOP combined with JK5G and JK21 postbiotics for gut microbiome modulation.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Liu X, Cheng D, Wang F (2025). Postbiotic-mediated gut microbiome modulation enhances R-CHOP efficacy in high-risk diffuse large B-cell lymphoma: a case report.. Discover oncology, 17(1), 169. https://doi.org/10.1007/s12672-025-04322-0
MLA Liu X, et al.. "Postbiotic-mediated gut microbiome modulation enhances R-CHOP efficacy in high-risk diffuse large B-cell lymphoma: a case report.." Discover oncology, vol. 17, no. 1, 2025, pp. 169.
PMID 41449247 ↗

Abstract

This case report describes an adult with high-risk DLBCL (IPI score 4) treated with R-CHOP combined with JK5G and JK21 postbiotics for gut microbiome modulation. The patient achieved significant tumor regression while maintaining stable hematological parameters. Microbial analysis demonstrated enrichment of beneficial genera (Veillonella, Bacteroides, Roseburia), potentially linked to postbiotic intervention. Notably, the regimen exhibited excellent tolerability without leukopenia or severe toxicities, suggesting postbiotics may enhance chemotherapy efficacy through microbiome-immune interactions while mitigating adverse effects. These findings warrant further investigation into postbiotics as adjuvant therapy for optimizing DLBCL treatment outcomes.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기